#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
South Carolina legislators are attempting to restrict the sale of high-THC hemp-derived products, but the effectiveness of state-level restrictions depends on federal action by Congress. Currently, the 2018 Farm Bill’s broad definition of legal hemp creates a regulatory gap that allows products containing up to 0.3% THC by dry weight to be sold without the controls applied to Schedule I cannabis, enabling manufacturers to circumvent state cannabis regulations through hemp-derived alternatives like delta-8 and delta-10 THC products. This regulatory inconsistency has raised public health concerns, particularly regarding uncontrolled product potency and pediatric access to intoxicating cannabinoids outside the medical cannabis framework. Clinicians should recognize that patients and families may be obtaining high-potency cannabis products through unregulated hemp channels, complicating clinical assessments of cannabis exposure and use patterns. Until Congress clarifies hemp regulations or state and federal authorities align their cannabis scheduling, physicians should inquire about hemp-derived product use when taking substance use histories, as these products may not be disclosed when patients are only asked about “legal cannabis” or “marijuana.”
“We’re seeing children present to emergency departments with cannabinoid hyperemesis syndrome and acute psychiatric symptoms from unregulated hemp products that contain THC levels comparable to traditional cannabis, yet these products sit on convenience store shelves with virtually no oversight, and until Congress acts on federal scheduling, state legislators are essentially working with one hand tied behind their back.”
? While South Carolina legislators debate restricting high-THC hemp products, clinicians should recognize that the current patchwork of state and federal cannabis regulations creates genuine uncertainty about product potency, labeling accuracy, and contaminant testing that directly affects patient safety and counseling. The gap between hemp-derived products (federally legal under 0.3% THC threshold) and more potent cannabis formulations means patients may not accurately report their actual cannabinoid exposure when discussing symptoms or medication interactions. Pediatric exposure incidents have risen as edible products become more accessible and less obviously identifiable as containing psychoactive substances, underscoring the importance of proactive screening and family education in primary care settings. Until clearer federal standards emerge, clinicians should document cannabis and hemp product use more deliberately during history-taking, counsel patients on product variability and potential harms, and remain alert to acute intoxication or cannabis hyperemesis syndrome presentations that
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
